A Phase II Study of Farnesyl Transferase Inhibitor R115777 (Zarnestra) (R115777 ( Zarnestra), Tipifarnib, R115777, NSC 702818) in Elderly Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia

Trial Profile

A Phase II Study of Farnesyl Transferase Inhibitor R115777 (Zarnestra) (R115777 ( Zarnestra), Tipifarnib, R115777, NSC 702818) in Elderly Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2013

At a glance

  • Drugs Tipifarnib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 08 Jan 2013 Primary endpoint added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Actual end date (1 Jan 2009) added as reported by ClinicalTrials.gov record.
    • 23 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top